Home LiteratureArticle Details
PMID: 15944316 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 174 ·No. 12 ·2005-06-15 ·Pages 8082-9

Oger S, Méhats C, Dallot E, Cabrol D, Leroy MJ

Abstract

Chorioamniotic infection is a leading cause of preterm premature rupture of fetal membranes (amnion and chorion). Bacterial infection induces an inflammatory response characterized by elevated production of proinflammatory cytokines; the latter activate the production of both PGs that stimulate uterine contractions, and matrix metalloproteinases (MMPs) that degrade the extracellular matrix of the chorioamniotic membranes. The inflammatory response is under the control of cAMP content, which is partly regulated by phosphodiesterases (PDE). In this study, we investigated the role of the PDE4 family in the inflammatory process triggered by LPS in a model of amniochorionic explants. We found that PDE4 family is the major cAMP-PDE expressed in human fetal membranes and that PDE4 activity is increased by LPS treatment. Selective inhibition of PDE4 activity affected LPS signaling, because PDE4 inhibitors (rolipram and/or cilomilast) reduced the release of the proinflammatory cytokine TNF-alpha and increased the release of the anti-inflammatory cytokine IL-10. PDE4 inhibition reduced cyclooxygenase-2 protein expression and PGE(2) production and also modulated MMP-9, a key mediator of the membrane rupture process, by inhibiting pro-MMP-9 mRNA expression and pro-MMP-9 activity. These results demonstrate that the PDE4 family participates in the regulation of the inflammatory response associated with fetal membrane rupture during infection. The PDE4 family may be an appropriate pharmacological target for the management of infection-induced preterm delivery.

MeSH Terms
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors,physiology Adjuvants, Immunologic/pharmacology,physiology Amnion/drug effects,enzymology,immunology,metabolism Chorion/drug effects,enzymology,immunology,metabolism Cyclic AMP/antagonists & inhibitors,physiology Cyclic Nucleotide Phosphodiesterases, Type 4 Cyclooxygenase 2 Dinoprostone/biosynthesis Enzyme Activation/drug effects,physiology Enzyme Precursors/metabolism Female Humans Immune Sera/pharmacology Interleukin-10/immunology,metabolism Lipopolysaccharides/immunology Matrix Metalloproteinase 9/metabolism Membrane Proteins Phosphodiesterase Inhibitors/pharmacology Pregnancy Prostaglandin-Endoperoxide Synthases/biosynthesis Rolipram/pharmacology Tissue Culture Techniques Tumor Necrosis Factor-alpha/antagonists & inhibitors,metabolism Up-Regulation/drug effects,immunology
Chemicals
Adjuvants, Immunologic Enzyme Precursors Immune Sera Lipopolysaccharides Membrane Proteins Phosphodiesterase Inhibitors Tumor Necrosis Factor-alpha Interleukin-10 Cyclic AMP Cyclooxygenase 2 PTGS2 protein, human Prostaglandin-Endoperoxide Synthases 3',5'-Cyclic-AMP Phosphodiesterases Cyclic Nucleotide Phosphodiesterases, Type 4 Matrix Metalloproteinase 9 Rolipram Dinoprostone
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Oger Stéphanie
Institut National de la Santé et de la Recherche Médicale, Unité 427, Faculté des Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris, France.
Méhats Céline
Dallot Emmanuelle
Cabrol Dominique
Leroy Marie-Josèphe
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
2005-06-15
Pages
8082-9
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com